Drug Trial Radar · NCT07007312
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,300
Planned (sponsor's estimate)
Start
Sep 26, 2025
Primary completion
Nov 2031
Study completion Nov 2031
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance. The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
ZiftomenibDrug
Oral administration
PlaceboDrug
Oral administration
VenetoclaxDrug
Oral administration
Azacitidine (AZA)Drug
Intravenous or subcutaneous administration
DaunorubicinDrug
Intravenous administration
Cytarabine (Ara-C)Drug
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)Time frame: Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion
- Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR)Time frame: Assessed up to 36 months after last patient inclusion
- Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)Time frame: Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion
- Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patientsTime frame: Assessed up to 36 months after last patient inclusion
Locations
141 sites in 17 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
University of California, Fresno
Clovis, California · Recruiting
University of California, San Diego
La Jolla, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
USC Norris Cancer Center
Los Angeles, California · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
University of California, Irvine
Orange, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Hartford HealthCare Cancer Institute
Hartford, Connecticut · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
University of Miami
Miami, Florida · Recruiting
Moffitt Cancer Center & Research Institute
Tampa, Florida · Recruiting
Northwestern
Chicago, Illinois · Not yet recruiting
University of Iowa
Iowa City, Iowa · Recruiting
University of Kansas
Fairway, Kansas · Recruiting
University of Kentucky
Lexington, Kentucky · Recruiting
MGH
Boston, Massachusetts · Recruiting
University of Massachusetts
Worcester, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Wayne State University School of Medicine
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
HealthPartners Cancer Center at Regions Hospital (MN)
Saint Paul, Minnesota · Recruiting
Rutgers Biomedical and Health Sciences
New Brunswick, New Jersey · Recruiting
University of New Mexico
Albuquerque, New Mexico · Recruiting
State University of New York at Buffalo
Buffalo, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University
New York, New York · Recruiting
Weill Cornell Medical Center
New York, New York · Recruiting
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Willamette Valley Cancer Institute
Eugene, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Baptist Clinical Research Institute
Memphis, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
TriStar Centennial Medical Center
Nashville, Tennessee · Recruiting
Texas Oncology-Austin Midtown
Austin, Texas · Recruiting
Texas Oncology-Presbyterian Cancer Center
Dallas, Texas · Recruiting
University of Texas
Houston, Texas · Recruiting
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.